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Abstract Mitochondrial respiratory chain deficiencies
are a group of more than 100 disorders of adults and
children, with highly variable phenotypes. The high prev-
alence of mitochondrial disorders (MIDs) urges the clini-
cian to diagnose these disorders accurately, which is
difficult in the light of highly variable and overlapping
phenotypes, transmission patterns and molecular back-
grounds. Fibroblast growth factor 21 (FGF-21) is an
important endocrine and paracrine regulator of metabolic
homeostasis. The FGF-21 transcript is reported to be
abundantly expressed in liver, but little is known about the
regulation of FGF-21 expression in other tissues. FGF-21
could play a role in the metabolic alterations that are often
associated with mitochondrial diseases. The aim of this
study was to show the association of the FGF-21 biomarker
with human primary MIDs and secondary MIDs in sus-
pected patients in Iran. Serum FGF-21 levels were
determined using ELISA in 47 mitochondrial patients,
including 32 with primary MIDs, 15 patients with Friedr-
eich ataxia as a secondary MID and 30 control subjects.
Serum FGF-21 levels were significantly higher in subjects
with the primary MIDs (p \ 0.05), compared to subjects
without MIDs. However, serum FGF-21 levels did not
show significant increase in subjects with FA as a sec-
ondary MID. There is an association between increasing
concentrations of FGF-21 with mitochondrial diseases,
suggesting FGF-21 as a biomarker for diagnosis of primary
MIDs in humans. However, this biomarker is not appro-
priate for the diagnosis of FA.
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Introduction
The human fibroblast growth factor (FGF) family includes
at least 22 members with diverse biological functions, such
as cell growth, cell differentiation, and wound healing [1].
Recent data has shown that this family may play important
roles in defining and regulating the functions of some
endocrine-relevant tissues and organs, as well as modu-
lating various metabolic processes [2].
FGF-21 has been identified as a potent metabolic regu-
lator [3]. Although the physiological role of FGF-21 in
humans is not understood, higher circulating levels are
strongly associated with certain metabolic states, where fat
is accumulated in the liver, triglycerides are high and HDL
cholesterol is low (all features associated with hepatos-
teatosis and dyslipidemia) [4]. FGF-21 is a recently iden-
tified player in carbohydrate and lipid metabolism [5–7].
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Mounting evidence from animal-based studies suggests
FGF-21 as a potent metabolic regulator with multiple
beneficial effects on obesity and diabetes [8, 9]. Serum
levels of FGF-21, which has been suggested as a potential
candidate for the treatment of diabetes, are increased in
obesity. In addition, there is a positive association of serum
FGF-21 levels with age, several parameters of adiposity
including BMI, waist circumference, waist-to-hip ratio, fat
percentage, insulin resistance, and adverse lipid profiles
[10].
FGF-21 is detected in fat [11] and muscle [12], and the
concept of FGF-21 as a novel hepatokine, adipokine and
even a myokine were suggested. However, FGF-21 is also
present in the exocrine pancreas and b-cells at drastically
higher levels than in the liver, adipose tissue and muscle
[13–15]. In skeletal muscles, FGF-21 protein expression is
essentially comparable to that of fasted liver. Hepatic FGF-
21 transcription is upregulated by fasting [16, 17], thus
skeletal muscle can be an important source of FGF-21 [12].
In this study, we measured and investigated the corre-
lation of FGF-21 concentrations in the sera of patients with
primary and secondary MIDs to assess whether it is a
feasible biomarker for human RCD.
Materials and methods
Patients with mitochondrial diseases were excluded by the
fact that these defects were the result of primary MIDs. The
genetic defect was established in mtDNA extracted from
muscle and blood using established techniques. Confirma-
tion of the mtDNA defect in each patient was sought but
was not required for inclusion, assuming the clinical fea-
tures were consistent and a pathogenic mutation had been
confirmed within the pedigree. This approach was vali-
dated by a near-100 % rate of positive genetic tests where
samples were available.
The suspected mitochondrial diseases were referred to
the Medical Genetics Department at the Special Medical
Center in Iran for investigation. Those with pathogenic
mtDNA mutations were identified. Some FA patients were
recruited as candidates for secondary MIDs because of the
link between FA and MID. A total of 30 control subjects
with no family history of MIDs were randomly selected.
Human FGF-21 enzyme-linked immunosorbent assay
(ELISA) kits were obtained from BioVendor Laboratory
Medicine (Modrice, Czech Republic). For the measure-
ment of FGF-21. Serum samples were diluted 1:3 before
the assay. Then, 100 ll of diluted sera, calibrators and
quality controls were added to 96-well microtiter plates
coated with an affinity-purified polyclonal anti-human
FGF-21 antibody. The assay was conducted according to
the manufacturer’s protocol.
A calibration curve was constructed by plotting the
absorbance values at 450 nm versus the FGF-21 concen-
trations of the calibrators, and concentrations of unknown
samples were determined using this calibration curve.
This assay was then used to measure serum FGF-21
levels in 47 Iranian mitochondrial disorders. In our study,
32 patients had primary MIDs and 15 patients had sec-
ondary MIDs (patients with FA). Our primary MID patients
showed a pathogenic mutation or an abnormally low RC
enzyme activity in muscle and had mitochondrial enceph-
alomyopathy, lactic acidosis, myoclonus, epilepsy, ragged-
red fibers mutation, point mutation, mtDNA deletions and
mtDNA depletion.
Results
The mean concentrations of FGF-21 in serum are 70 pg/ml
(range 15–309 pg/ml) in healthy adults and 114 pg/ml
(42–244 pg/ml) in healthy children, respectively [18].
Interestingly, patients with primary MIDs [346.2 pg/ml
(17.5–1707); n = 32] had significantly higher serum FGF-
21 levels than the controls [87.1 pg/ml (32–269.1);
n = 30] (Table 1). No significant difference in serum FGF-
21 levels was observed between FA patients and controls.
[FA patients (n = 15), 71.6 pg/ml (23.9–93.4) vs. controls
[87.1 pg/ml (32–269.1); n = 30] (Table 1).
There were gender differences in serum FGF-21 levels
[men (n = 17), median 261.4 pg/ml (interquartile range
17.5–1707] vs. women (n = 15), 442.4 pg/ml (25.2–
1,599.1) among patients with primary MIDs, and there were
no gender differences in serum FGF-21 levels [men (n = 9),
median 69.2 pg/ml (interquartile range 23.9–81.8) vs.
women (n = 6), 75.1 pg/ml (36.9–93.4) in FA patients]
(Table 1).
Discussion
Mitochondria are vital components of all nucleated cells
because of the presence of the respiratory chain (RC), and
are the major sites of energy production. Given the
Table 1 Correlations of serum FGF-21 levels with primary MIDs
and FA
Group Control Primary MIDs FA
Number of subjects 30 32 15
Gender (M/F) 17/13 17/15 9/6
FGF-21 level in male (pg/ml) 86.6 261.4 69.2
FGF-21 level in female (pg/ml) 88.7 422.4 75.1
FGF-21 level in all (pg/ml) 87.1 346.2 71.6
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complexity of RC genetic inheritance and its function and
regulation, a proper oxidative phosphorylation system
(OXPHOS) requires the full assembly of functional pro-
teins. Mutations of the nDNA and mtDNA genes encoding
the different RC sub-complexes and their regulatory factors
can produce a wide range of OXPHOS diseases with
extremely heterogeneous clinical manifestations [19]. RC
disorders are one of the most common causes of inherited
metabolic disorders [20]. Over 100 genes govern the pro-
cess of oxidative phosphorylation, and mutations in any of
these can cause a mitochondrial respiratory chain defect
[21].
It has become clear that OXPHOS may be impaired by
mutations in many mitochondrial and even non-mito-
chondrial proteins, or may be disturbed as a secondary
effect of other biochemical defects of intracellular metab-
olism [22]. OXPHOS defects caused by genes encoding
non-OXPHOS mitochondrial proteins, such as frataxin, are
responsible for FA [23]. FA is an autosomal recessive
neurodegenerative disease characterized by progressive
ataxia, neuropathy, skeletal abnormalities and cardiomy-
opathy. In FA, mutations in the nuclear gene encoding
frataxin, which is involved in iron homeostasis in mito-
chondria, result in severe deficiencies of iron–sulphur
clusters containing complexes I–III and of the Krebs cycle
enzyme aconitase [22]. Defects of intracellular metabo-
lism, particularly excess free radical generation, including
nitric oxide or peroxynitrite, may cause secondary damage
to the respiratory chain [22]. Other recessive nuclear
mutations are known to affect structural subunits or
assembly of mitochondrial respiratory chain complexes,
and only FA was included in our prevalence figures [23].
Clinical experience in mitochondrial diseases suggest
that *75 % of adult-onset mitochondrial diseases are a
consequence of primary mtDNA mutations [23]. The
clinical presentation of RCD is highly variable in severity,
age of onset, and the combination of organ systems
involved. The factors contributing to this variability are
poorly understood. Consequently, the diagnosis can be
challenging, and there are very limited means of objec-
tively monitoring disease progression [24]. Genetic disor-
ders with impaired OXPHOS are extremely heterogeneous,
as their clinical presentation ranges from lesions of single
tissues or specialized structures, such as the optic nerve in
mitochondrial DNA-associated Leber’s hereditary optic
neuropathy and in nuclear DNA-associated dominant optic
atrophy, to more widespread pathologies, including myo-
pathies, peripheral neuropathies, encephalomyopathies,
cardiopathies, or complex multisystem [25].
Increased concentrations of organic acids (particularly
lactic acid and TCA cycle intermediates) in blood, urine,
cerebrospinal fluid, as well as in tissues, are frequently
encountered in patients with OXPHOS deficiencies,
especially in children and in those with the most severe
biochemical defects [26]. Serum biomarkers for MIDs
include lactate, pyruvate, amino acids, creatine kinase, and
possibly serum creatine [18, 27]. The ratio of lactate to
pyruvate is sometimes raised, especially in children and in
adults with encephalomyopathies, but is frequently normal
in patients with progressive myopathies. Creatine kinase
concentrations in serum are occasionally increased in
people with mitochondrial diseases, mostly in the disorders
that cause muscle damage [18].
The sensitivity of FGF-21 in identifying mitochondrial
disorders with muscle involvement compared to those for
lactate, pyruvate, lactate to pyruvate ratio, and creatine
kinase suggest that the measurement of FGF-21 in serum
by ELISA would be a useful first-line test in patients with
suspected RCDs [18]. Recent evidence has indicated that
there is a direct association between daily physical activity
and serum FGF-21 levels [28]. There is also a positive
association between mitochondrial myopathy and increased
FGF-21 levels in the sera of mice [4]. Single RC-deficient
muscle fibers induce the expression of the metabolic reg-
ulator FGF-21, with increased levels also seen in mouse
plasma. These results strongly suggest that FGF-21
induction is a muscle-specific response, up-regulated
especially in RC-deficient fibers, and that FGF-21 expres-
sion increases upon the disease progression, suggesting that
their induction is related to the pathogenesis [4].
Suomalainen [18] presented a major step forward in the
investigative options for patients with mitochondrial
RCDs. They have focused their research on finding a bio-
marker to identify mitochondrial disease. In a mouse model
with mitochondrial myopathy, they found that FGF-21 was
induced in muscles and that concentrations in the serum
were raised [4]. FGF-21 in serum seems to be a sensitive
and specific quantitative biomarker for muscle pathology in
a wide range of mitochondrial disorders in adults and
children, including deficiencies in one or more of the
respiratory chain enzyme complexes in the skeletal muscle.
FGF-21 concentrations in serum seemed to increase with
increasing clinical severity of the mitochondrial disease
and muscle pathology [18]. Tyynismaa and colleagues [4]
detected a threefold increase of FGF-21 levels in Deletor
mice plasma, compared to controls. These results raised an
interesting possibility that FGF-21 could be secreted from
the diseased muscle fibers upon RC deficiency. RCD of
single or multiple complexes resulted in high concentra-
tions of FGF-21 in serum, including complex I deficiency,
which is the most common form [29]. Respiratory chain
defects induce FGF-21 expression in mouse skeletal mus-
cle, which leads to raised concentrations in serum [30].
Systemic availability of FGF-21 could play a role in the
metabolic alterations that are often are associated with
mitochondrial diseases [3].
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Conclusions
Our data showed that serum FGF-21 levels in patients with
primary MIDs were significantly higher than in control
subjects, but showed no significant difference between
patients with FA (as a secondary MID) than control sub-
jects. Among these primary MIDs, women had moderately
increased FGF-21 concentrations in serum. These results
support the role of FGF-21 as a key regulator of metabo-
lism in humans, and suggest that serum FGF-21 levels are
associated with mitochondrial diseases and can be poten-
tially used as a biomarker for primary MIDs. Although
FGF-21 concentrations in serum were useful to differenti-
ate patients with primary MIDs from healthy controls,
FGF-21 concentrations were unable to diagnose FA in
patients. This study provides the first clinical demonstra-
tion of the associations of serum FGF-21 levels with both
primary MIDs and FA in humans.
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